TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10332441
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily controlled release oxybutynin
Study: 8622042
Drug: CSF (granulocyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSF (granulocyte [G]- or granulocyte-macrophage [GM]-CSF)
Study: 8622042
Drug: Vincristine (cumulative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vincristine (cumulative dose in the first cycle)
Study: 1777913
Drug: Nisoldipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nisoldipine (10 mg 3 times daily)
Study: 6811379
Drug: Levonorgestrel 250
Normalized name: ethinyl estradiol 30 MCG / levonorgestrel 250 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levonorgestrel 250 μg combined with 30 μg ethinyl estradiol
Study: 6811379
Drug: Levonorgestrel 250
Normalized name: ethinyl estradiol 30 MCG / levonorgestrel 250 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levonorgestrel 250 μg combined with 20 μg ethinyl estradiol
Study: 28459717
Drug: Negative pressure
Normalized name: DRESSING,NEGATIVE PRESSURE WOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative pressure wound therapy (NPWT) via a novel negative pressure device
Study: 25425219
Drug: L-RISK diet
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-RISK diet (high in cereal fibre: 30-50 g/day and coffee: ≥ 5 cups/day, free of red meat)
Study: 25425219
Drug: H-RISK diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: H-RISK diet (low in fibre: ≤ 10 g/day, coffee-free, high in red meat: ≥ 150 g/day)
Study: 24676435
Drug: Treadmill exercise
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treadmill exercise (30 minutes, twice a week, moderate intensity of 60% VO₂max)
Study: 8799520
Drug: Oral strontium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral strontium chloride administration under fasting conditions (study I)
Study: 8799520
Drug: Oral strontium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral strontium chloride administration with a standardized meal (study II)
Study: 31202812
Drug: Daily intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily intake of vinegar
Study: 27341068
Drug: Progressive resistance
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Progressive resistance and balance exercise program (twice weekly for three months)
Study: 24124331
Drug: Intraduodenal glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraduodenal glucose infusion at 0 kcal/min
Study: 24124331
Drug: Intraduodenal glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraduodenal glucose infusion at 0.5 kcal/min
Study: 24124331
Drug: Intraduodenal glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraduodenal glucose infusion at 1.0 kcal/min
Study: 24124331
Drug: Intraduodenal glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraduodenal glucose infusion at 1.5 kcal/min
Study: 11701674
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of GH (0.05 mg/kg x d)
Study: 11701674
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of GH (0.025 mg/kg x d)
Study: 9156352
Drug: SC-52458 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC-52458 (200 mg)
Study: 9156352
Drug: SC-52458 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC-52458 (100 mg or more)
Study: 9156352
Drug: SC-52458 (10-150
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC-52458 (10-150 mg)
Study: 8251893
Drug: IFN +
Normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN + low-dose Ara-C
Study: 3102779
Drug: Metoclopramide, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide, 10 mg parenterally
Study: 28449228
Drug: AZA steady
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZA steady (2-2.5 mg/kg/day)
Study: 28449228
Drug: AZA down
Normalized name: Kool-Down
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZA down (1-1.25 mg/kg/day)
Study: 21484416
Drug: Serotonin reuptake
Normalized name: Selective serotonin reuptake inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serotonin reuptake inhibitor (SRI) medication
Study: 15214181
Drug: Normobaric hypoxitherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normobaric hypoxitherapy (NHT) combined with standard treatment in the basic group of 32 patients.
Study: 15214181
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment only in the control group of 20 patients.
Study: 8695078
Drug: PCINA for
Normalized name: Cina artemisia preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCINA for 4 hours followed by 5 hours of ward‐provided pain therapy (Group 1; n = 10)
Study: 8695078
Drug: Ward‐provided pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ward‐provided pain therapy for 5 hours followed by 4 hours of PCINA (Group 2; n = 10)
Study: 8695078
Drug: Ward‐provided pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ward‐provided pain therapy
Study: 6369524
Drug: High-dose methylprednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methylprednisolone (3.5 mg/kg/day)
Study: 6369524
Drug: Low-dose methylprednisolone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose methylprednisolone (1.0 mg/kg/day)
Study: 30269963
Drug: Capacitive resistive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capacitive resistive monopolar radiofrequency (CRMRF) treatment
Study: 30269963
Drug: Sham-CRMRF treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham-CRMRF treatment
Study: 26695724
Drug: Weekly iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly iron (100 mg), folic acid (500 mcg) and placebo for 26 weeks (Group A)
Study: 26695724
Drug: Weekly iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly iron (100 mg), folic acid (500 mcg) and cyanocobalamin (500 mcg for 6 weeks and 15 mcg for 20 weeks) for 26 weeks (Group B)
Study: 23761326
Drug: 400 IU
Normalized name: Vitamin D 400 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 IU of vitamin D3 daily
Study: 23761326
Drug: 800 IU
Normalized name: Vitamin E 800 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 IU of vitamin D3 daily
Study: 23761326
Drug: 1600 IU
Normalized name: Ascorbic Acid/Biotin/Calcium/Cholecalciferol/Cyanocobalamin/Folic Acid/Iodine/Niacin/Pantothenic Acid/Pyridoxine/Riboflavin/Thiamine/Vitamin A/Vitamin E/Zinc 40 MG-150 MCG-80 MG-600 IU-3 MCG-100 MCG-70 MCG-6 MG-2.5 MG-0.7 MG-0.8 MG-0.7 MG-1600 IU-10 IU-1.6 MG Oral Tablet, Chewable
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1600 IU of vitamin D3 daily
Study: 23761326
Drug: 2400 IU
Normalized name: lipase 2400 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2400 IU of vitamin D3 daily
Study: 20163197
Drug: Extended-release niacin
Normalized name: niacin Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release niacin (ERN) 2 g + laropiprant (LRPT) 40 mg
Study: 20163197
Drug: Extended-release niacin
Normalized name: niacin Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release niacin (ERN) 2 g
Study: 11848169
Drug: Guanabenz (GB;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanabenz (GB; 2-8 mg at 11 PM, n = 17)
Study: 10448876
Drug: Cranial radiation
Normalized name: geranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranial radiation (two doses)
Study: 8543717
Drug: Brief prevention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief prevention program (BP) consisting of 4 sessions of cognitive-behavioral therapy (CBT)
Study: 2337214
Drug: Local anaesthetic
Normalized name: Local anaesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anaesthetic solution prewarmed to 37 degrees C
Study: 2337214
Drug: Local anaesthetic
Normalized name: Local anaesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anaesthetic solution at room temperature
Study: 463893
Drug: Abrupt discontinuation
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abrupt discontinuation of lidocaine infusion (Group 1)
Study: 463893
Drug: Gradual tapering
Normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gradual tapering of lidocaine infusion over a three-hour period (Group 2)
Study: 463893
Drug: Lidocaine infusion
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine infusion for 36 hours or less
Study: 463893
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of abrupt cessation versus three-hour tapering of lidocaine infusion
Study: 31721601
Drug: Inactivated varicella-zoster
Normalized name: varicella/zoster immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated varicella-zoster virus (VZV) vaccine (ZVIN)
Study: 30935872
Drug: Closed-loop insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed-loop insulin delivery with faster-acting insulin aspart
Study: 30935872
Drug: Conventional subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional subcutaneous insulin therapy (control group)
Study: 28611343
Drug: PEG IFN
Normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PEG IFN 180 mcg weekly for 12 months (add-on therapy)
Study: 28611343
Drug: Tenofovir 300
Normalized name: tenofovir 300 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenofovir 300 mg orally daily (monotherapy)
Study: 21317934
Drug: Oral azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral azithromycin 250 mg daily for 12 weeks
Study: 12735919
Drug: Experimental formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental formulations of low calorie carbonated orange drinks
Study: 11549101
Drug: 14C-cholesterol-labeled AmBisome
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14C-cholesterol-labeled AmBisome (2 mg/kg, 1 microgCi/kg)
Study: 7879710
Drug: Whole herpes
Normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole herpes simplex vaccines
Study: 2849775
Drug: Fentanyl 0.1
Normalized name: fentanyl 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 0.1 mg/70 kg
Study: 2849775
Drug: Fentanyl 0.2
Normalized name: fentanyl 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 0.2 mg/70 kg
Study: 2849775
Drug: Fentanyl 0.25
Normalized name: bupivacaine-fentanyl 0.25%-20 mcg/mL-0.9% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 0.25 mg/70 kg
Study: 603271
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose heparin (5000 units two hours before operation and 5000 units every 12 hours following operation for five days)
Study: 603271
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose heparin postoperatively only
Study: 31655314
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (exercise followed by massage)
Study: 23786558
Drug: Continuous ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous ketamine (0.2 mg/kg/hour)
Study: 12638394
Drug: Vardenafil 20
Normalized name: vardenafil 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vardenafil 20 mg after overnight fast
Study: 12638394
Drug: Vardenafil 20
Normalized name: vardenafil 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vardenafil 20 mg after high-fat breakfast
Study: 12638394
Drug: Vardenafil 20
Normalized name: vardenafil 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vardenafil 20 mg on empty stomach in the evening
Study: 12638394
Drug: Vardenafil 20
Normalized name: vardenafil 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vardenafil 20 mg after moderate-fat meal in the evening
Study: 10879639
Drug: Azithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (500 mg bid on the 1st day, followed by 500 mg once daily for the next 4 days)
Study: 10879639
Drug: Doxycycline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (100 mg bid for 14 days)
Study: 1378136
Drug: Carvedilol (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (25 mg b.i.d.)
Study: 1378136
Drug: Propranolol-ISDN (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol-ISDN (80 mg/20 mg b.i.d.)
Study: 28555251
Drug: Milk protein
Normalized name: Milk protein
DrugBank: Casein (DB10516)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk protein supplement (SUPP)
Study: 26086284
Drug: Translaryngeal injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Translaryngeal injection (TLI) technique
Study: 21584955
Drug: Alflutop (intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alflutop (intramuscular injections) + peloid applications
Study: 10878147
Drug: Time‐averaged daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time‐averaged daily calcium intake (500 to 1500 mg/day)
Study: 8410764
Drug: Prototype filament
Normalized name: Yucca filamentosa extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prototype filament suspension design toothbrush (active suspension)
Study: 8410764
Drug: Prototype filament
Normalized name: Yucca filamentosa extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prototype filament suspension design toothbrush (inactive suspension)
Study: 3516668
Drug: Cognitive‐Behavior Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive‐Behavior Therapy
Study: 28275117
Drug: Parsatuzumab (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parsatuzumab (400 mg) in combination with mFOLFOX6 plus bevacizumab (5 mg/kg)
Study: 28275117
Drug: Placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in combination with mFOLFOX6 plus bevacizumab (5 mg/kg)
Study: 18222671
Drug: Aescin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aescin and troxerutin combination treatment
Study: 12725561
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose of SHR-5 Rhodiola rosea extract (2 capsules)
Study: 12725561
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose of SHR-5 Rhodiola rosea extract (3 capsules)
Study: 11089761
Drug: Nebulized ET(A)
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized ET(A) receptor antagonist (LU‐135252, 3 mg/kg, inhaled over 1 h)
Study: 11089761
Drug: Nebulization of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulization of saline (5-10 ml inhaled over 1 h)
Study: 8093824
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (Zuclopenthixol acetate, Haloperidol, Zuclopenthixol)
Study: 3690045
Drug: High sodium
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High sodium intake (16 to 20 g)
Study: 29513635
Drug: Strip-type bleaching
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strip-type bleaching agent
Study: 29513635
Drug: Paint-on-type bleaching
Normalized name: Castellani Paint
DrugBank: Phenol (DB03255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paint-on-type bleaching agent
Study: 29513635
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment groups (strip, paint-on, and controls)
Study: 20543751
Drug: Isomaltulose (ISO),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isomaltulose (ISO), 75 g, GI = 32
Study: 17138192
Drug: IA morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IA morphine 5 mg
Study: 18505564
Drug: Antidepressants (specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants (specific agents not mentioned)
Study: 10848717
Drug: Phase II
Normalized name: Coxiella burnetii phase II Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase II and III clinical trial programme (specific agents not mentioned)
Study: 7758059
Drug: Diclofenac dispersible
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac dispersible 50 mg three times daily for 3 to 7 days
Study: 2204776
Drug: Methyldopa (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methyldopa (250 mg b.i.d.)
Study: 2204776
Drug: Urapidil (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urapidil (30 mg b.i.d.)
Study: 386697
Drug: Proglumide (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proglumide (1200 mg/day)
Study: 386697
Drug: Magnesium trisilicate
Normalized name: Magnesium Trisilicate
DrugBank: Magnesium trisilicate (DB09281)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium trisilicate (1320 mg/day)
Study: 386697
Drug: Proglumide (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proglumide (1200 mg/day) and Magnesium trisilicate (1320 mg/day)
Study: 27925466
Drug: Low-concentration iodinated
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-concentration iodinated contrast agent (270 mgI/ml) and low tube current (120 mA)
Study: 27925466
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose protocol (370 mgI/ml) and conventional tube current (160 mA)
Study: 21143588
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (oral information only)
Study: 16433875
Drug: ACIDFORM gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACIDFORM gel (5 g, intravaginally once daily for five consecutive days)
Study: 16433875
Drug: Metronidazole gel
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole gel (10%, intravaginally once daily for five consecutive days)
Study: 16433875
Drug: ACIDFORM gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACIDFORM gel
Study: 14506625
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human IGF-I (15 microg/kg body weight/d twice daily)
Study: 10981173
Drug: Low-dose spironolactone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose spironolactone
Study: 10981173
Drug: Selective aldosterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective aldosterone antagonists
Study: 31987323
Drug: 80 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg/kg VE
Study: 25080462
Drug: Low-dose recombinant
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose recombinant human growth hormone (rhGH) (0.05 mg · kg⁻¹ · d⁻¹)
Study: 22722511
Drug: Oxygen-enriched air
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen-enriched air inhalation (normobaric hyperoxia of 40% fraction of inspired oxygen)
Study: 22722511
Drug: Regular air
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular air inhalation (21% fraction of inspired oxygen)
Study: 22722511
Drug: Oxygen-enriched air
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen-enriched air inhalation
Study: 22722511
Drug: Regular air
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular air inhalation
Study: 20398563
Drug: L-carnitine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (5 g/d intravenously for seven days)
Study: 18779465
Drug: DM-specific personal
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DM-specific personal health record (PHR) that imported clinical and medications data, provided patient-tailored decision support, and enabled the patient to author a 'Diabetes Care Plan' for electronic submission to their physician.
Study: 15625373
Drug: Carboplatin-paclitaxel combination
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin-paclitaxel combination
Study: 15625373
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy in performance status 2 patients
Study: 1450310
Drug: Saline (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (0.1 cc/kg) administered to Group 1 (G1) patients 3 minutes prior to intubation
Study: 1450310
Drug: Lidocaine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (1 mg/kg) administered to Group 2 (G2) patients 3 minutes prior to intubation
Study: 27214664
Drug: Dipraglurant (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipraglurant (50 mg once daily)
Study: 27214664
Drug: Dipraglurant (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipraglurant (100 mg 3 times daily)
Study: 26037427
Drug: Protocol-based standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol-based standard therapy (ST)
Study: 22786751
Drug: Zibotentan 10
Normalized name: Zibotentan
DrugBank: Zibotentan (DB06629)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zibotentan 10 mg/day
Study: 18678157
Drug: Valpromide (medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valpromide (medication group)
Study: 12463967
Drug: L-thyroxine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-thyroxine treatment for 6 months until normalization of TSH
Study: 10472236
Drug: Tetracaine gel
Normalized name: Tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tetracaine gel 1 g applied for 45 min
Study: 10472236
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream 2 g applied for 60 min
Study: 9121999
Drug: L-thyroxin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-thyroxin treatment
Study: 1830636
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg oestradiol valerate combined with cyproterone acetate, medroxyprogesterone acetate or levonorgestrel
Study: 1830636
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg 17 beta‐oestradiol combined with desogestrel
Study: 7258218
Drug: Alcohol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (2 ml/kg of body weight)
Study: 26991724
Drug: Daily isometric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily isometric hand grip exercises before chemotherapy
Study: 26991724
Drug: Daily isometric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily isometric hand grip exercises